Unjha Formul.

Which are the latest news on Unjha Formul.?

Why is Unjha Formulations Ltd falling/rising?

As of 20-Jun, Unjha Formulations Ltd's stock price is 19.00, showing a slight increase but significantly underperforming against the Sensex. Despite recent short-term gains, the stock remains in a bearish trend with a year-to-date decline of 24.00%.

As of 20-Jun, Unjha Formulations Ltd's stock price is currently at 19.00, reflecting a slight increase of 0.03 (0.16%). Despite this small rise, the stock has been underperforming compared to the benchmark Sensex, which has increased by 1.69% over the past week. Over the last month, the stock has shown a minimal decline of 0.11%, while year-to-date, it has fallen significantly by 24.00%, compared to the Sensex's decline of 9.88%.<BR><BR>Today, the stock has experienced a consecutive gain over the last two days, with an overall return of 8.26% during this period. However, it is important to note that the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend in the longer term.<BR><BR>Additionally, while there has been a rise in investor participation, with delivery volume increasing by 21.5% against the 5-day average, the stock's performance today has still underperformed its sector by 0.56%. This combination of factors suggests that while there may be short-term gains, the overall trend for Unjha Formulations Ltd remains concerning, contributing to its recent price movements.

How big is Unjha Formul.?

As of 10th June, Unjha Formulations Ltd has a market capitalization of 9.00 Cr, with recent net sales of 15.59 Cr and a net profit of 0.71 Cr. The balance sheet for March 2025 shows shareholder's funds of 3.14 Cr and total assets of 4.56 Cr.

As of 10th June, Unjha Formulations Ltd has a market capitalization of 9.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Unjha Formulations reported Net Sales of 15.59 Cr and a Net Profit of 0.71 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 3.14 Cr and Total Assets of 4.56 Cr.

Who are in the management team of Unjha Formul.?

The management team of Unjha Formul includes Krutiben M Patel (Managing Director), Jashodaben S Patel (Chairman), and several independent directors: Hasmukh C Chavda, Jitendrakumar Parshottamdas Limbachiya, and Mustufa Najmuddin, along with Esham Patel (Additional Director) and Jigar Ray (Company Secretary & Compliance Officer).

The management team of Unjha Formul includes the following individuals:<BR><BR>1. **Krutiben M Patel** - Managing Director<BR>2. **Jashodaben S Patel** - Chairman (Non-Executive)<BR>3. **Hasmukh C Chavda** - Independent Director<BR>4. **Jitendrakumar Parshottamdas Limbachiya** - Independent Director<BR>5. **Mustufa Najmuddin** - Independent Director<BR>6. **Esham Patel** - Additional Director<BR>7. **Jigar Ray** - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Unjha Formul.?

Unjha Formul.'s peers include Ortin Global, Colinz Labs, Beryl Drugs, Ganga Pharma, Vivanza Biosci, Decipher Labs, Brawn Biotech, and Saroja Pharma In. Unjha Formul. has average management risk and growth, with a 1-year return of -10.64%, better than Vivanza Biosci but worse than Ortin Global's 62.21%.

Peers: The peers of Unjha Formul. are Ortin Global, Colinz Labs, Beryl Drugs, Ganga Pharma., Vivanza Biosci., Decipher Labs, Brawn Biotech, and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Ortin Global, Colinz Labs, Beryl Drugs, Ganga Pharma., Vivanza Biosci., Decipher Labs, Brawn Biotech, and the rest. Average management risk is found at Unjha Formul. and Saroja Pharma In. Below Average growth is noted for Ortin Global, Colinz Labs, Beryl Drugs, Ganga Pharma., Decipher Labs, Brawn Biotech, and the rest, while Average growth is seen at Vivanza Biosci. and Unjha Formul. Good capital structure is present at Colinz Labs and Unjha Formul., while Below Average capital structure is noted for Ortin Global, Beryl Drugs, Ganga Pharma., Vivanza Biosci., Decipher Labs, Brawn Biotech, Saroja Pharma In, and the rest.<BR><BR>Return Snapshot: Ortin Global has the highest 1-year return at 62.21%, while Vivanza Biosci. has the lowest at -29.75%, with Unjha Formul.'s 1-year return at -10.64% being better than Vivanza Biosci. but worse than Ortin Global. Additionally, the six-month return is negative for Unjha Formul., Ganga Pharma., Vivanza Biosci., Decipher Labs, and Brawn Biotech.

What does Unjha Formul. do?

Unjha Formulations Ltd is a micro-cap pharmaceutical company specializing in Isabgol (Psyllium) products, with recent net sales of 3 Cr and a net loss of 1 Cr for the quarter ending March 2026. The company has a market cap of INR 9 Cr and a P/E ratio of 12.00.

Overview: <BR>Unjha Formulations Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of pharmaceutical formulations, particularly Isabgol (Psyllium) products.<BR><BR>History: <BR>Unjha Formulations Limited was established in June 1987 as a Partnership firm. The company has been a pioneer in Isabgol (Psyllium) formulation and is currently reporting its financial results for the quarter ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 9 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 12.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.43 <BR>Return on Equity: 18.49% <BR>Price to Book: 2.33<BR><BR>Contact Details: <BR>Address: Khali Char Rasta, State Highway Ta Sidhpur Patan Gujarat : 384151 <BR>Tel: 91-2767-282395 <BR>Email: info@unjhaformulations.com <BR>Website: http://www.unjhaformulations.com

Are Unjha Formulations Ltd latest results good or bad?

Unjha Formulations Ltd's latest Q4 FY26 results show a 38.40% revenue growth to ₹3.28 crores, but the company reported a net loss of ₹0.74 crores, worsening from the previous year's loss. Despite the revenue increase, the widening losses and declining operating margin indicate significant operational challenges, making the results unfavorable.

Unjha Formulations Ltd's latest results for Q4 FY26 indicate a challenging situation for the company. While the revenue showed a significant year-on-year growth of 38.40%, reaching ₹3.28 crores, the company reported a net loss of ₹0.74 crores, which is a deterioration from a loss of ₹0.41 crores in the same quarter last year. This widening loss raises concerns about the company's operational efficiency.<BR><BR>Moreover, the operating margin fell to -13.72%, marking the lowest level in recent quarters, which suggests that the company is struggling with cost management despite the increase in sales. Additionally, there was a notable decline in revenue of 25.62% compared to the previous quarter, further highlighting the volatility in the company's performance.<BR><BR>Overall, while the revenue growth is a positive sign, the inability to convert that growth into profitability and the significant losses indicate that the latest results are not favorable for Unjha Formulations. The operational challenges and financial metrics suggest a need for serious attention to improve the company's financial health.

Should I buy, sell or hold Unjha Formulations Ltd?

When is the next results date for Unjha Formulations Ltd?

Unjha Formulations Ltd will announce its results on 04 February 2026.

Unjha Formulations Ltd is scheduled to declare its results on 04 February 2026.

How has been the historical performance of Unjha Formul.?

Unjha Formul's historical performance has shown fluctuations in net sales and profits, with net sales decreasing to 13.86 Cr in March 2025 from 18.50 Cr in March 2024, but profit after tax increased to 0.41 Cr. Despite volatility, the company improved its profitability metrics and shareholder equity during this period.

Answer:<BR>The historical performance of Unjha Formul shows fluctuations in key financial metrics over the years, with notable changes in net sales, operating profit, and profit after tax.<BR><BR>Breakdown:<BR>Unjha Formul's net sales have varied significantly, reaching 13.86 Cr in March 2025, down from 18.50 Cr in March 2024, but up from 13.15 Cr in March 2023. The total operating income followed a similar trend, with a peak in March 2024. The raw material costs decreased to 11.32 Cr in March 2025 from 15.55 Cr in March 2024, contributing to a total expenditure of 13.35 Cr in March 2025, down from 17.92 Cr the previous year. Operating profit, excluding other income, improved to 0.51 Cr in March 2025, while profit before tax rose to 0.52 Cr, leading to a profit after tax of 0.41 Cr, an increase from 0.28 Cr in both March 2024 and March 2023. The company's total assets decreased to 4.56 Cr in March 2025 from 4.93 Cr in March 2024, with total liabilities also declining to 4.56 Cr. The book value per share increased to 7.01 in March 2025, reflecting a positive trend in shareholder equity, which rose to 3.14 Cr from 2.73 Cr in March 2024. Overall, while Unjha Formul experienced some volatility in sales and profits, it showed improvements in profitability metrics and shareholder value over the observed period.

Is Unjha Formul. overvalued or undervalued?

As of November 12, 2025, Unjha Formul. is considered undervalued with a PE ratio of 11.08 and a PEG ratio of 0.40, significantly outperforming peers like Sun Pharma. and Divi's Lab., and demonstrating strong long-term returns of 149.21% over three years and 250.28% over five years, despite recent underperformance year-to-date.

As of 12 November 2025, the valuation grade for Unjha Formul. has moved from very expensive to very attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 11.08, an EV to EBIT of 10.66, and an impressive ROE of 32.48%. <BR><BR>In comparison to its peers, Unjha Formul. stands out with a PEG ratio of 0.40, while Sun Pharma. Inds. has a PE of 35.94 and Divi's Lab. shows a staggering PE of 69.64, both categorized as expensive. The attractive valuation of Unjha Formul. is further supported by its strong performance metrics, particularly its ROCE of 16.80%. Despite recent underperformance in the YTD return compared to the Sensex, the long-term performance over 3 years and 5 years shows a remarkable return of 149.21% and 250.28%, respectively, reinforcing the attractiveness of its current valuation.

Who are the top shareholders of the Unjha Formul.?

The top shareholder of Unjha Formul is Jashodaben Shambhubhai Patel with 16.51%, followed by public shareholder Esha Mayank Patel at 1.6%. Individual investors collectively hold 56.1%, with no pledged promoter holdings or participation from mutual funds or foreign institutional investors.

The top shareholders of Unjha Formul include Jashodaben Shambhubhai Patel, who holds the highest stake at 16.51%. Following her, the highest public shareholder is Esha Mayank Patel with a holding of 1.6%. Additionally, individual investors collectively hold a significant portion of the company at 56.1%. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor participation.

What is the technical trend for Unjha Formul.?

As of June 6, 2025, Unjha Formul's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bullish weekly indicators and mildly bearish monthly indicators.

As of 6 June 2025, the technical trend for Unjha Formul has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish. The weekly RSI indicates bullish momentum, but the monthly RSI shows no signal. Bollinger Bands are bullish in both weekly and monthly views, suggesting potential upward movement. However, daily moving averages are mildly bearish, indicating short-term weakness. The KST shows a mildly bullish trend weekly but is mildly bearish monthly. Dow Theory indicates no trend in both weekly and monthly assessments. Overall, the indicators reflect a sideways movement with no strong bullish or bearish bias at this time.

Has Unjha Formul. declared dividend?

No Dividend History Available